Calcium Gluconate (Calcium Gluconate) Patent Expiration, LOE Window & CMS Spending
Calcium Gluconate (Calcium Gluconate) by Fresenius Kabi: FDA Orange Book LOE 2037-07-25, 6 AB generics, $17.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | N208418 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2037-07-25 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $17.9M |
| 2024 Medicare Part D Spend | $62K |
| 2024 Medicaid Spend | $17.8M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 19.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.